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Does mass drug administration of azithromycin reduce child
mortality?
Child mortality remains prevalent in low-income
and middle-income countries, with the sub-Saharan
Africa region accounting for the largest under-5
mortality rates.1 Although under-5 mortality rates have
significantly decreased, most countries in sub-Saharan
Africa with high mortality rates are unlikely to achieve
the Sustainable Development Goal of at least as low as
25 deaths per 1000 livebirths by 2030.2
Mass administration of azithromycin is one of the
key interventions in trachoma control programmes
and potentially reduces child mortality in sub-Saharan
Africa.3,4 Several trials done in sub-Saharan Africa
have reported mixed efficacy of mass administration
of azithromycin in reducing child mortality at a
population level.4 On the basis of this evidence, WHO,
in 2020, recommended against the universal mass
administration of azithromycin except for biannual
administration for children aged 1–11 months in
countries with high child mortality and where existing
child survival interventions are also strengthened.3
In The Lancet Global Health, Patricia Pavlinac and
colleagues5 did an individually randomised, doubleblind, placebo-controlled trial to assess the effect of a
5-day course of azithromycin administered at hospital
discharge on the risk of death and rehospitalisation
in the subsequent 6-month period among children
aged 1–59 months.5 In the study, eligible children
from four hospitals in Kenya were randomly assigned
to receive either azithromycin (oral suspension
10 mg/kg on day 1, followed by 5mg/kg per day on
days 2–5) or placebo, with the first dose being directly
observed. Caregivers administered and recorded the
subsequent doses and returned the bottles at the
3-month follow-up. They also provided information
on the child’s medical history during the 3-months
and 6-months post-discharge follow-up visits, when
whole stool or flocked rectal swabs were also collected
to assess for azithromycin resistance in Escherichia coli
isolates. Pavlinac and colleagues’ study is one of the
few assessing the effects of mass administration of
azithromycin in individual-level randomised trials. The
authors found that, despite a high risk of mortality and
readmission in the study population, azithromycin did

not have beneficial effects on the combined outcome
of readmission or mortality, with an incidence of death
or rehospitalisation of 20·4 per 100 child-years in the
azithromycin group versus 22·5 per 100 child-years
in the placebo group (adjusted hazard ratio 0·91,
95·5% CI 0·64–1·29, p=0·58), even after adjusting for
medication adherence.5
The protective effect of mass administration of
azithromycin has only been shown in population-wide
cluster randomised trials, with no beneficial effect
shown in one trial done in combination with seasonal
malaria chemoprophylaxis,4 which could explain the
difference in the findings. Additionally, most children in
the study were treated with antibiotics during hospital
admission and were discharged home with antibiotics,
possibly affecting the potential effect of azithromycin.
Regardless, this new evidence does not preclude the
potentially beneficial effects of mass administration of
azithromycin on child mortality or hospitalisation, as
the study was not sufficiently powered to detect these
effects independently and at the population level.
Similar to earlier studies showing that mass
administration of azithromycin might propagate
antimicrobial resistance,6 Pavlinac and colleagues found
a concerningly high rate of azithromycin resistance in
commensal Escherichia coli at baseline (37·7% in both
study groups) and at 3 months post-randomisation,
especially in the azithromycin group (26·9%) compared
with the placebo group (19·1%; adjusted prevalence
ratio 1·41, 95% CI 0·95–2·09, p=0·088).5 This was despite
very low use of azithromycin during hospitalisation
and study inclusion restricted to children at high risk of
rehospitalisation and mortality. Concerns that mass drug
administration will lead to the selection of macrolideresistant strains of endemic diseases and resistance to
macrolides and other classes of antimicrobials in other
pathogens are real barriers to further implementation.
This reflects the growing evidence of increasing
antimicrobial resistance among children7 and raises
concerns because most countries in sub-Saharan Africa
do not have robust antimicrobial surveillance systems.
As more research on the potential effects of
azithromycin is done, phenotype-drug resistance profiles
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for multiple organisms need to be integrated to provide
robust evidence on antimicrobial resistance due to the
mass administration of azithromycin.6 Importantly,
the issues of community-wide azithromycin resistance
should be of concern to policy makers and health
practitioners, especially due to the recent use of
azithromycin in some settings in sub-Saharan Africa for
the management of COVID-19.8
It is increasingly clear that more research is needed
to understand the specific mechanisms of action of
azithromycin in reducing child mortality. Additionally,
an assessment of the overall and age-specific effects
of azithromycin on child mortality and morbidity
in high quality, individually randomised, placebo
controlled trials among children younger than 5 years
is urgently needed to clarify the continued use of mass
administration of azithromycin given the low level of
evidence and risk for antibiotic resistance.
In general, child mortality is a complex public health
issue, with multiple determinants that affect the health
and wellbeing of children. Despite evidence that the mass
administration of azithromycin effectively reduces child
mortality at the population level for specific treatable
endemic diseases such as trachoma,4 it is unlikely
to be the magic pill that can independently reduce
child mortality in sub-Saharan Africa. Downstream
interventions to improve key determinants of health,
including immunisation, nutrition, and access to clean
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and safe water, need to be strengthened to reduce the
persistent disparities in child mortality across and within
countries.
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